Essayer OR - Gratuit

THE HIDDEN RISKS OF AMERICA'S MOST POPULAR PRESCRIPTION PAINKILLER

Mint Mumbai

|

December 26, 2025

Gabapentin has soared in popularity as an alternative to opioids, but patients are finding it can cause harm

- Betsy McKay & Shalini Ramachandran

THE HIDDEN RISKS OF AMERICA'S MOST POPULAR PRESCRIPTION PAINKILLER

While the medical establishment has mostly maintained that gabapentin isn't habit-forming, some patients have reported debilitating adverse effects when they try to taper off it.

(istockphoto)

John Avery was just back from a guys’ golfing weekend and doing dead lifts at the gym in 2023 when he felt a pop in his lower back. A disc had slipped and was pressing on a nerve.

After months of rest, physical therapy and steroids, he was prescribed a drug called gabapentin by a pain management specialist who told Avery that it could help calm his nerve pain and that it was “nonaddictive,” Avery recalled. He took the medicine for a few days, then had surgery, and took it again for a little more than three weeks.

The 33-year-old former high-school physical education teacher in Newark, Ill., said he experienced a severe protracted withdrawal when he stopped, which led to neurological symptoms now that make his original back problem seem like “a paper cut” by comparison.

His symptoms include shaking and a burning sensation throughout his body, muscle spasms and a racing pulse. He can’t sleep for more than a half-hour at a time, and has lost so much weight that his wife said his calves are the size of her arms.

The change in his life, he said, is “beyond dramatic.”

Approved by the Food and Drug Administration decades ago for seizures and nerve pain from shingles, gabapentin is now the seventh-most widely prescribed drug in the U.S., according to the Iqvia Institute for Human Data Science. About 15.5 million people were prescribed gabapentin in 2024, according to an analysis by Centers for Disease Control and Prevention researchers.

Studies show that most of the prescriptions are written to treat conditions that it wasn't approved for—a practice that is legal and common, but means the FDA hasn't vetted its risks and benefits for those purposes.

PLUS D'HISTOIRES DE Mint Mumbai

Mint Mumbai

Mint Mumbai

Kedaara leads race to acquire Tynor Ortho

Private equity firm Kedaara Capital has emerged as the front-runner to acquire a majority stake in Tynor Orthotics, the Mohali-based manufacturer of fracture aids and body braces, three people familiar with the matter said.

time to read

1 mins

January 08, 2026

Mint Mumbai

Mint Mumbai

Centre seeks fare data from airlines

The central government has asked IndiGo, Air India, SpiceJet and Akasa to provide data on average fares charged, a document shows, as antitrust authorities investigate unprecedented travel disruptions in December.

time to read

1 mins

January 08, 2026

Mint Mumbai

Mint Mumbai

WHERE SHOULD YOU INVEST ₹10 LAKH TODAY?

Mint asked money managers this simple question. Find out what they said about the future of investing

time to read

7 mins

January 08, 2026

Mint Mumbai

Mint Mumbai

Budget may pitch ₹10,000 cr plan to build girls' hostels

Millions of girls fall out of India's education system after school, simply because there is no safe and affordable place for them to live near college.

time to read

2 mins

January 08, 2026

Mint Mumbai

Mint Mumbai

Faster FY26 growth likely; nominal GDP below goal

At 7.4%, FY26 may beat last fiscal's 6.5%; but nominal GDP seen at a muted 8%

time to read

3 mins

January 08, 2026

Mint Mumbai

Mint Mumbai

Toothless Trai can't make telcos pay fines

India's telecom regulator has ramped up penalties on operators, but its crusade to improve service quality, compliance and contain spam is stalling.

time to read

3 mins

January 08, 2026

Mint Mumbai

Mint Mumbai

Faster growth likely; nominal GDP below goal

“What stands out from the current year’s growth forecast is the robust 7.8% growth in investments,

time to read

1 mins

January 08, 2026

Mint Mumbai

Bandra Bay emerges as the next luxury realty hotspot

Bandra Bay, pegged to be the next real estate luxury hotspot in Mumbai, will witness a project-launching spree of high-end residential towers from top developers in the coming months.

time to read

2 mins

January 08, 2026

Mint Mumbai

Mint Mumbai

Govt moves to unclog highway disputes

The government has set up a dedicated early dispute resolution panel to speed up the settlement of small-value disputes worth about ₹20,000 crore that have slowed highway development in the country

time to read

2 mins

January 08, 2026

Mint Mumbai

India's growth seen at 6.6% in FY27: D&B

India’s economy is expected to enter a phase of relative stability in FY27, with growth hoiding at around 6.6%, as consumption, public investment and a revival in private capital expenditure (capex) sustain momentum amid global uncertainty, Dun & Bradstreet (D&B) said.

time to read

1 min

January 08, 2026

Listen

Translate

Share

-
+

Change font size